Darius Kharabi
Known title: CHIEF BUSINESS OFFICERCIK: 0001893729
Associated companies
Transaction History
| KALA | ▼ Sell | Open Market | 20,806 | $17K | 10/22/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 4,511 | $18K | 6/24/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 730 | $3K | 6/3/2025 | View on chart |
| KALA | ▲ Buy | Grant | 10,100 | $0 | 1/6/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 2,021 | $15K | 1/6/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 5,158 | $25K | 6/26/2024 | View on chart |
| KALA | ▼ Sell | Open Market | 231 | $1K | 5/31/2024 | View on chart |
| KALA | ▲ Buy | Grant | 4,600 | $0 | 1/4/2024 | View on chart |
| KALA | ▼ Sell | Open Market | 1,385 | $9K | 1/4/2024 | View on chart |
| KALA | ▲ Buy | Grant | 36,847 | $0 | 6/22/2023 | View on chart |
| KALA | ▲ Buy | Grant | 2,648 | — | 5/31/2023 | View on chart |
| KALA | ▲ Buy | Grant | 6,977 | — | 3/10/2023 | View on chart |
| KALA | ▲ Buy | Grant | 9,525 | $0 | 1/4/2023 | View on chart |
| KALA | ▼ Sell | Other | 9 | — | 2/15/2022 | View on chart |
| KALA | ▲ Buy | Grant | 295,657 | — | 11/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
KALA Bio Signs LOI to Acquire Telehealth Platform
KALA Bio shares surged 57% after hours following the announcement of a non-binding letter of intent to acquire a nationwide telehealth platform. The target company has generated approximately $48 million in sales since inception. Additionally, the company signed a separate agreement to resell genetic testing products through a U.S. DNA testing platform.
KALA Bio Signs LOI to Acquire Telehealth Platform. KALA Bio shares surged 57% after hours following the announcement of a non-binding letter of intent to acquire a nationwide telehealth platform. The target company has generated approximately $48 million in sales since inception. Additionally, the company signed a separate agreement to resell genetic testing products through a U.S. DNA testing platform.